×
It looks like you're accessing our website from North America. We have a dedicated page tailored to your region, offering the most relevant information and services.
If you have an existing eCom account, you can log in to the North American site using your current username and password.
Would you like to visit the North America page?
You can access the page here
If you have any questions, please feel free to contact our support team hytest@hytest.fi
All Hytest SARS-CoV-2 nucleoprotein (NP) antibodies (Cat. #3CV4), including monoclonal antibodies (MAbs) C706, C524, C518, C715, and C527, target the N-terminal part of the nucleoprotein, specifically the region N47-A173.
The BA.4 variant contains the following mutations and deletions in the NP: P13L, del31/33, P151S, R203K, G204R, and S413R (all information about SARS-CoV-2 NP mutations is from https://outbreak.info/situation-reports).
Both the BA.2.86 (Pirola) and EG.5 (Eris) variants carry the following mutations in NP: P13L, del31/33, R203K, G204R, and S413R. Additionally, FLiRT group variants (KP.3, KP.3.3, KP.2, and KP.1.1), as well as similar new variants (LB.1, KS.1.1, and the XEC variant—a combination of KS.1.1 and KP.3.3), have mutations and deletions in NP, including: P13L, del31/33, R203K, G204R, Q229K, and S413R. Importantly, no additional mutations have been observed in the N47-A173 region.
In conclusion, Hytest SARS-CoV-2 NP antibodies (Cat. #3CV4: MAbs C706, C524, C518, C715, and C527) should reliably detect the Pirola and Eris variants, FLiRT group variants (KP.3, KP.3.3, KP.2, and KP.1.1), as well as the similar new variants LB.1, KS.1.1, and XEC.
Copyright © Hytest Ltd.